medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-31-20-24medalphabet-2312Research ArticleСтатьиЭффективность комбинации с эрибулином в третьей линии химиотерапии тройного негативного рака молочной железы (описание случая)Effectiveness of combination with eribulin in third line of chemotherapy for triple negative breast cancer (case report)https://orcid.org/0000-0002-8281-5646КалугинМ. В.KaluginM. V.

Калугин Максим Вячеславович, врач-онколог

Москва

Kalugin Maxim V., oncologist

Moscow

https://orcid.org/0000-0001-7087-2435ИвановаК. А.IvanovaK. A.

Иванова Кристина Анатольевна, врач-ординатор

Москва

Ivanova Kristina A., resident physician

Moscow

ivanova_ka7@mail.ruhttps://orcid.org/0000-0001-8907-1523БорисоваЕ. И.BorisovaE. I.

Борисова Елена Ивановна, к.м.н., с.н.с.

Москва

Borisova Elena I., PhD Med, senior researcher

Moscow

https://orcid.org/0000-0002-4674-2558НахапетянС. С.NakhapetyanS. S.

Нахапетян Сусана Сетраковна, врач-ординатор

Москва

Nakhapetyan Susana S., resident physician

Moscow

https://orcid.org/0000-0001-5912-1155ГуторовС. Л.GutorovS. L.

Гуторов Сергей Львович, д.м.н., вед.н.с. 

Москва

Gutorov Sergey L., DM Sci (habil.), lead researcher

Moscow

ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава РоссииРоссияNational Medical Research Centre of Oncology n.a. N.N. BlokhinRussian Federation202106122021131«Диагностика и онкотерапия» (3)2024Copyright © Калугин М.В., Иванова К.А., Борисова Е.И., Нахапетян С.С., Гуторов С.Л., 20212021Калугин М.В., Иванова К.А., Борисова Е.И., Нахапетян С.С., Гуторов С.Л.Kalugin M.V., Ivanova K.A., Borisova E.I., Nakhapetyan S.S., Gutorov S.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2312

В большинстве случаев метастатический тройной негативный рак молочной железы характеризуется агрессивным течением и ранним развитием резистентности к химиотерапии. Соответственно выбор варианта «поздних» линий лечения, как правило после антрациклинов и таксанов, проблематичен в связи с ограниченным набором эффективных и малотоксичных цитостатиков. На наш взгляд, в этой ситуации опционально применение эрибулина, обладающего уникальными противоопухолевыми механизмами. В качестве иллюстрации представлен случай достижения выраженного эффекта эрибулина при метастатическом раке молочной железы тройного негативного фенотипа, резистентного к предшествующим линиям химиотерапии.

In most cases triple negative breast cancer is characterized by an aggressive course of disease and early development of resistance to chemotherapy. Thereafter, the late-line treatment choice, usually after anthracyclines and taxanes, is problematic due to the limited amount of effective and low-toxic cytostatics. In our opinion, in this situation the use of eribulin which possesses unique antitumor action mechanisms is a good option. An illustrative case of a pronounced antitumor effect of eribulin in metastatic breast cancer with triple negative phenotype resistant to previous lines of chemotherapy is presented.

рак молочной железытройной негативныйэрибулинbreast cancertriple negative phenotypeeribulinReferencesSharma P. Biology and Management of Patients with Triple-Negative Breast Cancer. Oncologist. 2016 Sep; 21 (9): 1050–62. DOI: 10.1634/theoncologist.Sharma P. Biology and Management of Patients with Triple-Negative Breast Cancer. Oncologist. 2016 Sep; 21 (9): 1050–62. DOI: 10.1634/theoncologist.Baser O., Wei W., Xie L., et al. Retrospective study of patients with metastatic triple-negative breast cancer: survival, health care utilization, and cost. Commun. Oncol. 2012; 9: 8–14.Baser O., Wei W., Xie L., et al. Retrospective study of patients with metastatic triple-negative breast cancer: survival, health care utilization, and cost. Commun. Oncol. 2012; 9: 8–14.Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; Impassion 130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. 2016–0067 N Engl J Med. 2018 Nov 29; 379 (22): 2108–2121. DOI: 10.1056/ NEJMoa1809615. Epub 2018 Oct 20.Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; Impassion 130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. 2016–0067 N Engl J Med. 2018 Nov 29; 379 (22): 2108–2121. DOI: 10.1056/ NEJMoa1809615. Epub 2018 Oct 20.Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Aug 10; 377 (6): 523–533. DOI: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Aug 10; 377 (6): 523–533. DOI: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.Инструкция по медицинскому применению препарата Халавен® (РУ ЛП 001782 от 28.07.2012, с изменениями от 08.02.2017).Instructions for the medical use of Halaven® (RU LP 001782 of 07/28/2012, as amended on 02/08/2017). (In Russ.)Ekaterina L. Grishchuk, Maxim I. Molodtsov, Fazly I. Ataullakhanov, J. Richard McIntosh. (2005). Force production by disassembling microtubules. Nature. 438, 384–388.Ekaterina L. Grishchuk, Maxim I. Molodtsov, Fazly I. Ataullakhanov, J. Richard McIntosh. (2005). Force production by disassembling microtubules. Nature. 438, 384–388.Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E 7389) investigators. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12; 377 (9769): 914–23. DOI: 10.1016/S 0140–6736(11)60070–6. Epub 2011 Mar 2.Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E 7389) investigators. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12; 377 (9769): 914–23. DOI: 10.1016/S 0140–6736(11)60070–6. Epub 2011 Mar 2.Manso L, Moreno Antón F, Izarzugaza Perón Y. et al. Safety of eribulin as thirdline chemotHerapy in Her2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J. 2019; 00: 1–7 DOI: 10.1111/tbj.13199.Manso L, Moreno Antón F, Izarzugaza Perón Y. et al. Safety of eribulin as thirdline chemotHerapy in Her2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J. 2019; 00: 1–7 DOI: 10.1111/tbj.13199.O’Shaughnessy J., Miles D., Gray R. J. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J. Clin. Oncol. 2010; 28 (suppl 15): abstr 1005.O’Shaughnessy J., Miles D., Gray R. J. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J. Clin. Oncol. 2010; 28 (suppl 15): abstr 1005.Hardy-Bessard AC, Brocard F, Clatot F, Lortholary A, You B, Grenier J, Martin-Babau J, Lucas B, Meunier J, Ferrero JM, Savoye AM, Marti A, Despax R, Moullet I, Emile G. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study. Breast. 2020 Dec; 54: 256–263. DOI: 10.1016/j.breast.2020.09.011. Epub 2020 Sep 30. PMID: 33188992; PMCID: PMC 7672314.Hardy-Bessard AC, Brocard F, Clatot F, Lortholary A, You B, Grenier J, Martin-Babau J, Lucas B, Meunier J, Ferrero JM, Savoye AM, Marti A, Despax R, Moullet I, Emile G. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study. Breast. 2020 Dec; 54: 256–263. DOI: 10.1016/j.breast.2020.09.011. Epub 2020 Sep 30. PMID: 33188992; PMCID: PMC 7672314.De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, Gamucci T, De Placido P, Poggio F, Russo S, Forestieri V, Lauria R, De Santo I, Michelotti A, Del Mastro L, De Laurentiis M, Giuliano M, De Placido S, Arpino G. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open. 2021 Feb 15; 6 (2): 100054. DOI: 10.1016/j.esmoop.2021.100054. Epub ahead of print. PMID: 33601296.De Angelis C, Bruzzese D, Bernardo A, Baldini E, Leo L, Fabi A, Gamucci T, De Placido P, Poggio F, Russo S, Forestieri V, Lauria R, De Santo I, Michelotti A, Del Mastro L, De Laurentiis M, Giuliano M, De Placido S, Arpino G. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open. 2021 Feb 15; 6 (2): 100054. DOI: 10.1016/j.esmoop.2021.100054. Epub ahead of print. PMID: 33601296.

The authors declare that there are no conflicts of interest present.